Research

Advanced Medical Research Center

Advanced Medical Research Center(SENTANKEN)conducts basic studies aimed at overcoming cancer and lifestyle diseases and translational researches which applies the scientific finding to clinical medicine. It has three omics centers – genomics, proteomics, cellomics –and a biobank, collaborates within YCU and with other research institutions, and promote translational researches. AMRC is also involved in a number of R&D, working with the industry. Our goal is to make our research findings available to the society without delay.

Outline, Structure & Function of the Advanced Medical Research Center >
RESEARCH > ADVANCED MEDICAL RESEARCH CENTER

Message from the Director

The Advanced Medical Research Center (SENTANKEN) of Yokohama City University(YCU) was established in 2006. The assignment of SENTANKEN is to facilitate advanced medical research associated with diseases such as cancer and lifestyle-related diseases. SENTANKEN is focused on basic researches in the field of genomics, proteomics and cellomics, as well as translational researches, which can fill the gap between basic and clinical researches, and promotes not only intramural collaboration but also between government, industry and academia.

Our goal is to make an attractive YCU that can contribute to the community by delivering the research outcomes of our basic and clinical researches promptly to the citizens of Yokohama and by connecting these activities for the revitalization of industries in Yokohama.

Departments & Divisions

 

Research News

2022-03-23

The 23rd Comparative Glycome Research Meeting in Yokohama: Glycome Meets Synthetic Biology and Frontiers

On Saturday, August 21, 2021, the 23rd Comparative Glycomics Research Meeting was held at the Training Center of Sail Training Ship NIPPON MARU (Yokohama, Japan). A total of 50 participants onsite and online, including participants from Japan, the United States of America, Belgium, and China, were connected for eight presentations and discussions.
2021-12-02

Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: a systematic review and network meta-analysis

It remains unclear which sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are most effective for preventing cardiovascular and renal events in type 2 diabetes mellitus (T2DM) patients, depending on the presence of albuminuria. We conducted a network meta-analysis to compare the efficacy of these two drug classes in T2DM patients with/without albuminuria.
2021-12-02

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients

Patients with type 2 diabetes mellitus (T2DM) and obesity are at high risk of developing cardiovascular disease (CVD). Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter (SGLT-2) inhibitors have been shown to prevent CVD in T2DM patients.
 
Contact info

E-mail
sentan@yokohama-cu.ac.jp
Our location

3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004 Japan

Access >